KLS Keeping Law Simple Legislation in plain English

Straight-ahead summaries built from the official bill text. We keep the source links front and center and leave the decision up to you.

Back to Oregon

HB2385 • 2025

Prohibits drug manufacturers from interfering directly or indirectly with a pharmacy or drug outlet acquiring 340B drugs, delivering 340B drugs to certain health care providers or dispensing 340B drugs.

Prohibits drug manufacturers from interfering directly or indirectly with a pharmacy or drug outlet acquiring 340B drugs, delivering 340B drugs to certain health care providers or dispensing 340B drugs.

Enacted

This bill passed the Legislature and reached final enactment based on the latest official action.

Sponsor
Representative Nosse,, Senator Patterson, Representative Diehl,, Gamba,, Gomberg,, Javadi,, Pham H,, Senator Manning Jr,
Last action
2025-06-23
Official status
Chapter Number Assigned
Effective date
Not listed

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

Prohibits drug manufacturers from interfering directly or indirectly with a pharmacy or drug outlet acquiring 340B drugs, delivering 340B drugs to certain health care providers or dispensing 340B drugs.

<b>Digest: The Act tells drug makers not to take actions that make it hard for a drug store to get certain drugs for health care providers, deliver the drugs to the providers, or dispense the drugs.

What This Bill Does

  • <b>Digest: The Act tells drug makers not to take actions that make it hard for a drug store to get certain drugs for health care providers, deliver the drugs to the providers, or dispense the drugs.
  • Makes it a civil penalty to violate the Act.
  • (Flesch Readability Score: 71.0).</b> [<i>Digest: The Act tells drug makers not to take actions that make it hard for a drug store to get certain drugs for health care providers, deliver the drugs to the providers or dispense the drugs.
  • (Flesch Readability Score: 62.5).</i>] Prohibits drug manufacturers from interfering directly or indirectly with a pharmacy or drug outlet acquiring 340B drugs, delivering 340B drugs to certain health care providers or dispensing 340B drugs.

Limits and Unknowns

  • This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Bill History

  1. 2025-06-23 House

    Chapter 297, (2025 Laws): effective on the 91st day following adjournment sine die.

  2. 2025-06-11 House

    Governor signed.

  3. 2025-06-03 House

    Speaker signed.

  4. 2025-06-03 Senate

    President signed.

  5. 2025-06-02 House

    House concurred in Senate amendments and repassed bill. Ayes, 35; Nays, 20--Boice, Boshart Davis, Breese-Iverson, Cate, Drazan, Edwards, Elmer, Evans, Harbick, Helfrich, Levy B, Lewis, Osborne, Owens, Reschke, Ruiz, Scharf, Skarlatos, Smith G, Yunker; Excused, 4--Marsh, McIntire, Nguyen H, Wallan.

  6. 2025-05-28 Senate

    Motion to substitute Minority Report for Committee Report failed. Ayes, 12; Nays, 18--Broadman, Campos, Frederick, Gelser Blouin, Golden, Gorsek, Jama, Lieber, Manning Jr, Meek, Neron Misslin, Patterson, Pham, Prozanski, Reynolds, Sollman, Taylor, President Wagner.

  7. 2025-05-28 Senate

    Third reading. Carried by Patterson. Passed. Ayes, 17; Nays, 13--Anderson, Bonham, Broadman, Girod, Hayden, Linthicum, McLane, Nash, Robinson, Smith DB, Starr, Thatcher, Weber.

  8. 2025-05-28 Senate

    Vote explanation(s) filed by Sollman.

  9. 2025-05-27 Senate

    Second reading.

  10. 2025-05-23 Senate

    Recommendation: Do pass with amendments to the A-Eng bill. (Printed B-Eng.) Hayden, Linthicum not concurring.

  11. 2025-05-23 Senate

    Minority Recommendation: Do pass with different amendments to the A-Eng bill. (Printed B-Eng. Minority)

  12. 2025-05-13 Senate

    Work Session held.

  13. 2025-05-08 Senate

    Public Hearing held.

  14. 2025-05-06 Senate

    Public Hearing held.

  15. 2025-04-15 Senate

    First reading. Referred to President's desk.

  16. 2025-04-15 Senate

    Referred to Health Care.

  17. 2025-04-14 House

    Third reading. Carried by Nosse. Passed. Ayes, 37; Nays, 18--Boice, Boshart Davis, Breese-Iverson, Drazan, Edwards, Elmer, Harbick, Helfrich, Levy B, Lewis, McIntire, Osborne, Reschke, Scharf, Skarlatos, Smith G, Wallan, Yunker; Excused, 4--Cate, Evans, Nguyen H, Walters; Excused for Business of the House, 1--Owens.

  18. 2025-04-14 House

    Vote explanation(s) filed by Nelson.

  19. 2025-04-09 House

    Rules suspended. Carried over to April 14, 2025 Calendar.

  20. 2025-04-08 House

    Second reading.

  21. 2025-04-07 House

    Recommendation: Do pass with amendments and be printed A-Engrossed.

  22. 2025-04-01 House

    Work Session held.

  23. 2025-03-11 House

    Public Hearing held.

  24. 2025-01-17 House

    Referred to Behavioral Health and Health Care.

  25. 2025-01-13 House

    First reading. Referred to Speaker's desk.

Official Summary Text

<b>Digest: The Act tells drug makers not to take actions that make it hard for a drug store to get certain drugs for health care providers, deliver the drugs to the providers, or dispense the drugs. Makes it a civil penalty to violate the Act. (Flesch Readability Score: 71.0).</b>
[<i>Digest: The Act tells drug makers not to take actions that make it hard for a drug store to get certain drugs for health care providers, deliver the drugs to the providers or dispense the drugs. (Flesch Readability Score: 62.5).</i>]
Prohibits drug manufacturers from interfering directly or indirectly with a pharmacy or drug outlet acquiring 340B drugs, delivering 340B drugs to certain health care providers or dispensing 340B drugs. Prohibits drug manufacturers from requiring utilization review data from a drug outlet or pharmacy as a condition of the acquisition, delivery or dispensation of a 340B drug.
<b>Creates a civil penalty imposed by the State Board of Pharmacy for violations of the provisions of the Act.</b>
Takes effect on the 91st day following adjournment sine die.
Relating to: Relating to restrictions on 340B covered entities; and prescribing an effective date.
Current location: Chapter Number Assigned

Current Bill Text

Read the full stored bill text 
83rd OREGON LEGISLATIVE ASSEMBLY--2025 Regular Session
Enrolled
House Bill 2385
Sponsored by Representative NOSSE, Senator PATTERSON; Representatives DIEHL, GAMBA,
GOMBERG, JAVADI, PHAM H, Senator MANNING JR (Presession filed.)
CHAPTER .................................................
AN ACT
Relating to restrictions on 340B covered entities; and prescribing an effective date.
Be It Enacted by the People of the State of Oregon:
SECTION 1.
(1) As used in this section:
(a) “Covered entity” has the meaning given that term in 42 U.S.C. 256b(a)(4).
(b) “Manufacturer” has the meaning given that term in ORS 646A.689.
(c) “340B drug” means a drug that has been subject to an offer of a reduced price by a
manufacturer pursuant to 42 U.S.C. 256b and is purchased by a covered entity.
(d) “Utilization review” has the meaning given that term in ORS 743B.001.
(2) A manufacturer or third party on behalf of a manufacturer may not:
(a) Deny, restrict, prohibit or otherwise interfere directly or indirectly with the acquisi-
tion of a 340B drug, delivery of a 340B drug to or dispensation of a 340B drug by a pharmacy
that has contracted with a covered entity to receive and dispense 340B drugs on behalf of the
covered entity in this state unless the acquisition delivery or dispensation is prohibited by
the United States Department of Health and Human Services.
(b) Require, either directly or indirectly, a covered entity to submit a claim or utilization
review data as a condition for the acquisition of a 340B drug by, delivery of a 340B drug to
or dispensation of a 340B drug by a pharmacy that has contracted with a covered entity to
receive and dispense 340B drugs on behalf of the covered entity in this state unless the
claims or utilization review data submission is required by the United States Department of
Health and Human Services.
SECTION 2.
(1) In addition to any other liability or penalty provided by law, the State
Board of Pharmacy may impose a civil penalty for any violation of section 1 of this 2025 Act.
A civil penalty imposed under this section may not exceed $5,000 per day on a manufacturer
for each violation.
(2) All penalties recovered under this section shall be deposited into the State Board of
Pharmacy Account established in ORS 689.139.
(3) Any civil penalty under this section shall be imposed in the manner provided in ORS
183.745.
SECTION 3. This 2025 Act takes effect on the 91st day after the date on which the 2025
regular session of the Eighty-third Legislative Assembly adjourns sine die.
Enrolled House Bill 2385 (HB 2385-B) Page 1
Passed by House April 14, 2025
Repassed by House June 2, 2025
..................................................................................
Timothy G. Sekerak, Chief Clerk of House
..................................................................................
Julie Fahey, Speaker of House
Passed by Senate May 28, 2025
..................................................................................
Rob Wagner, President of Senate
Received by Governor:
........................M.,........................................................., 2025
Approved:
........................M.,........................................................., 2025
..................................................................................
Tina Kotek, Governor
Filed in Office of Secretary of State:
........................M.,........................................................., 2025
..................................................................................
Tobias Read, Secretary of State
Enrolled House Bill 2385 (HB 2385-B) Page 2